{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:53:57Z","timestamp":1790610837429,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009459","name":"Society for Anthropological Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.esmoop.2025.105542","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T07:18:22Z","timestamp":1759303102000},"page":"105542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial"],"prefix":"10.1016","volume":"10","author":[{"given":"Y.Y.","family":"Janjigian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kawazoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"S.","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-P.","family":"Metges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.S.","family":"Wyrwicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ostapenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2850-6997","authenticated-orcid":false,"given":"M.","family":"Bilici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Lowery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4100-7673","authenticated-orcid":false,"given":"Y.","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-S.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-4531","authenticated-orcid":false,"given":"S.Y.","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2025.105542_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-019-0737-2","article-title":"Progress and challenges in HER2-positive gastroesophageal adenocarcinoma","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"9742","key":"10.1016\/j.esmoop.2025.105542_bib2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"7890","key":"10.1016\/j.esmoop.2025.105542_bib3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"issue":"10418","key":"10.1016\/j.esmoop.2025.105542_bib4","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.105542_bib5","series-title":"Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-line Treatment in Patients with HER2-positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","author":"Merck","year":"2024"},{"key":"10.1016\/j.esmoop.2025.105542_bib6","series-title":"FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer. 2021","year":"2021"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105542_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105542_bib8","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.22.02331","article-title":"Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO Guideline","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105542_bib9","series-title":"European Commission approves KEYTRUDA (pembrolizumab) plus trastuzumab and chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma expressing PD-L1 (CPS \u22651)","year":"2025"},{"key":"10.1016\/j.esmoop.2025.105542_bib10","series-title":"FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS \u22651)","year":"2025"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105542_bib11","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1634\/theoncologist.2014-0058","article-title":"Quality of life in the trastuzumab for gastric cancer trial","volume":"19","author":"Satoh","year":"2014","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105542_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100189","article-title":"Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric\/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study","volume":"6","author":"van Cutsem","year":"2021","journal-title":"ESMO Open"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105542_bib13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1200\/JCO.2023.41.4_suppl.286","article-title":"Rationale 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC\/GEJC)","volume":"41","author":"Moehler","year":"2023","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.esmoop.2025.105542_bib14","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.1200\/JCO.23.00170","article-title":"Health-related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric\/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649","volume":"41","author":"Moehler","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105542_bib15","doi-asserted-by":"crossref","first-page":"S854","DOI":"10.1016\/j.annonc.2023.09.1429","article-title":"Health-related quality of life (hrqol) analysis from KEYNOTE-859: first-line (1L) pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma","volume":"34","author":"Lowery","year":"2023","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:11:31Z","timestamp":1777623091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925014115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2059702925014115"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105542","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105542","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates and The Author(s).  Published by Elsevier Ltd. on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105542"}}